Evidence-based medicine: Can it be applied to stimulation of erythropoiesis for patients with malignancy?

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 3 SPEC. ISS., 2005, Pages 439-448

  Rizzo, J D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Darbepoetin; Erythropoiesis; Erythropoietin; Evidence based decision making; Health care

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER PATIENT; CHRONIC KIDNEY FAILURE; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; ERYTHROPOIESIS; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN DETERMINATION; HUMAN; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; RESOURCE ALLOCATION;

EID: 15844393902     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.01.021     Document Type: Review

References (37)

1. F.K. Lin S. Suggs C.H. Lin et al. Cloning and expression of the human erythropoietin gene Proc Natl Acad Sci USA 82 1985 7580-7584
2. K. Jacobs C. Shoemaker R. Rudersdorf et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin Nature 313 1985 806-810
3. D.P. Hamilton S. Hensley Mysterious illness opens a new front in Amgen-J&J war Wall Street Journal 241 2003 A1-A6
4. D.L. Sackett W.M. Rosenberg J.A. Gray et al. Evidence based medicine: what it is and what it isn't BMJ 312 1996 71-72
5. US Preventive Services Task Force Guide to Clinical Preventive Services 2nd edn 1996 Williams & Wilkins Baltimore
6. M. Hewitt J.V. Simone (eds.) Ensuring Quality Cancer Care. Jan 1, 1999 2004 National Academy Press Institute of Medicine Report, 1-12. http://www.nap.edu/books/0309064805/html/ accessed Jan 5, 2004
7. Crossing the quality chasm: A new health system for the 21st century. Commission on Quality of Healthcare in America. March 2001. National Academy Press. Institute of Medicine Report, 1-8. http://www.iom.edu/includes/DBFile.asp?id=4124 accessed Jan 5, 2004.
8. J.E. Wennberg M.M. Cooper The Dartmouth Atlas of Health Care 1998 1998 American Hospital Publishing Chicago
9. G.T. O'Connor H.B. Quinton N.D. Traven et al. Geographic variation in the treatment of acute myocardial infarction: The Cooperative Cardiovascular Project JAMA 281 1999 627-633
10. J.D. Birkmeyer S.M. Sharp S.R. Finlayson et al. Variation profiles of common surgical procedures Surgery 124 1998 917-923
11. J.R. Adams L.S. Elting D. Lyons et al. Evaluation of EPO use and direct-to-consumer marketing effects: Results from a survey of American and International Hematologists and Oncologists Proc Am Soc Clin Oncol 20 2001 249a
12. Federal Register. Vol. 67, No. 212, 66817-66867. November 1, 2002.
13. J. Seidenfeld M. Piper C. Flamm et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials J Natl Cancer Inst 93 2001 1204-1214
14. J.D. Rizzo A.E. Lichtin S.H. Woolf et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology Blood 100 2002 2303-2320
15. J. Bohlius S. Langensiepen G. Schwarzer et al. Erythropoietin for patients with malignant disease Cochrane Database Syst Rev 2004 CD003407
16. P.J. Hesketh F. Arena D. Patel et al. Front-loaded darbepoetin alfa with Q3W maintenance administered as a fixed or weight-based dose in anemic cancer patients results in similar efficacy profiles Proc Am Soc Clin Oncol 22 2003 731a
17. B.C. Mirtsching J.T. Beck V. Charu et al. Darbepoetin alfa administered every two weeks (Q2W) reduces chemotherapy-induced anemia (CIA) to the same extent as recombinant human erythropoietin (rHuEPO) but with less-frequent dosing Proc Am Soc Clin Oncol 22 2003 732 (abstr)
18. J. Patton M. Kuzur W. Liggett et al. Epoetin alfa 60,000 u once weekly followed by 120,000 u every three weeks maintains hemoglobin levels in anemic cancer patients receiving chemotherapy: Final report Proc Am Soc Clin Oncol 22 2003 754a
19. A. Besarab W.K. Bolton J.K. Browne et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584-590
20. M. Henke R. Laszig C. Rube et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial Lancet 362 2003 1255-1260
21. L.T. Goodnough The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy Nephrol Dial Transplant 17 supplement 5 2002 14-18
22. D.A. Weinstein C.N. Roy M.D. Fleming et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease Blood 100 2002 3776-3781
23. A. Major F. Mathez-Loic R. Rohling et al. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin Br J Haematol 98 1997 292-294
24. P.T. Silberstein T.E. Witzig J.A. Sloan et al. Weekly erythropoietin for patients with chemotherapy induced anemia: A randomized, placebo-controlled trial in the North Centeral Cancer Treatment Group Proc Am Soc Clin Oncol 21 2002 356a
25. J.L. Teruel R. Marcen J.F. Navarro et al. Evolution of serum erythropoietin after androgen administration to hemodialysis patients: A prospective study Nephron 70 1995 282-286
26. A. Gascon J.J. Belvis F. Berisa et al. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis Geriatr Nephrol Urol 9 1999 67-72
27. S.H. Ballal D.T. Domoto D.C. Polack et al. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease Am J Kidney Dis 17 1991 29-33
28. T.J. Littlewood E. Bajetta J.W. Nortier et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2001 2865-2874
29. L. Fallowfield D. Gagnon M. Zagari et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy Br J Cancer 87 2002 1341-1353
30. D. Cella M.J. Zagari C. Vandoros et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population J Clin Oncol 21 2003 366-373
31. J. Vansteenkiste R. Pirker B. Massuti et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 2002 1211-1220
32. A. Becker P. Stadler R.S. Lavey et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas Int J Radiat Oncol Biol Phys 46 2000 459-466
33. H. Frommhold R. Guttenberger M. Henke The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience Strahlenther Onkol 174 supplement 4 1998 31-34
34. K.E. Dusenbery W.A. McGuire P.J. Holt et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer Int J Radiat Oncol Biol Phys 29 1994 1079-1084
35. C.M. Glaser W. Millesi G.V. Kornek et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx Int J Radiat Oncol Biol Phys 50 2001 705-715
36. D. Antonadou E. Cardamakis M. Puglisi et al. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies Eur J Cancer 37 2001 144
37. J.U. Blohmer F. Wurschmidt U. Petry et al. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: Sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for pts with high-risk cervical cancer Proc Am Soc Clin Oncol 22 2003 447